Seeking Alpha

Nektar Therapeutics (NKTR +0.8%) is a beneficiary of the FDA's approval of Affymax's (AFFY...

Nektar Therapeutics (NKTR +0.8%) is a beneficiary of the FDA's approval of Affymax's (AFFY +35.4%) peginesatide treatment of anemia in dialysis patients. Nektar has an exclusive agreement under which it will provide Affymax with its proprietary technology for use in the drug's manufacture in exchange for manufacturing revenue, milestone and other payments.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)